title: Complete atrioventricular block secondary to bortezomib use in multiple myeloma.
abstract: Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of complete atrioventricular block while receiving bortezomib. We immediately stopped bortezomib, and after inserting a permanent VDD pacemaker, the patients' symptoms disappeared.
authors.affiliation: Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea.
authors.forename: Won-Seop
authors.initials: WS
authors.lastname: Lee
authors.forename: Dae-Hyeok
authors.initials: DH
authors.lastname: Kim
authors.forename: Sung-Hee
authors.initials: SH
authors.lastname: Shin
authors.forename: Seoung-Il
authors.initials: SI
authors.lastname: Woo
authors.forename: Jun
authors.initials: J
authors.lastname: Kwan
authors.forename: Keum-Soo
authors.initials: KS
authors.lastname: Park
authors.forename: Sang-Don
authors.initials: SD
authors.lastname: Park
authors.forename: Hyeon-Gyu
authors.initials: HG
authors.lastname: Yi
authors.forename: Sang-Hoon
authors.initials: SH
authors.lastname: Jeon
mesh_terms: D054537:Atrioventricular Block / Q000139:chemically induced*; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib